Bandit Weiss is the Chief Morale Officer at Marin Biologic Laboratories. Bandit has successfully been with the company and the Weiss family for a couple of years. He is lively and always keeps the team focused on being present, having fun and smiling. Bandit is a regular member of the Executive team meetings and contributes positively. Bandit is proactive and works for rewards. He has trained the team to support his needs.
Tania Weiss completed studies at the University of Michigan-Ann Arbor, with a B.S., M.S. and Ph.D., all in Chemistry or Biochemistry. She successfully worked in academia at the University of Chicago, Departments of Biochemistry and Molecular Biology; at Stanford University, Department of Biological Sciences; and at the University of California-San Francisco (UCSF), Department of Medicine. As adjunct faculty member at UCSF, Dr. Tania Weiss, built and staffed her own academic research laboratory and then subsequently founded and over the past 25 years systematically built and refined Marin Biologic Laboratories, Inc. CRO services and manufacturing businesses.
During her post-doctoral training at the University of Chicago with Eugene Goldwasser Ph.D., she was the first internationally to generate and characterize important new monoclonal antibodies specifically directed against erythropoietin and further trained with Drs Robert Shimke Ph.D. and Leonard Herzenberg Ph.D. in Stanford University’s flow cytometry and molecular biology laboratories. Dr. Len Herzenberg made major advances in research in clinical immunology and cell biology and is perhaps best known for developing advanced technology for fluorescence flow cytometry and hybridomas and made a very significant number of important and fundamental discoveries in lymphocyte biology.
Tania has published many significant papers, abstracts and patents. Also, she is often a speaker at national scientific conferences and chaired both the San Francisco Bioscience Forum and the American Association of Pharmaceutical Scientists. In 1995, Dr. Weiss became one of the few woman-founded and -owned private CRO’s, Marin Biologic Laboratories, Inc. Tania Weiss has a very solid reputation with the FDA and in providing successful creative and cost-effective solutions to client problems and generating world class results.
Peter completed his B.A. and M.S. in Physics at Yale University and the University of California-Berkeley, respectively and his Ph.D. in Biology at the Massachusetts Institute of Technology. Dr. Ralph has held academic positions at the Salk Institute for Biological Studies in La Jolla, CA and Sloan Kettering Institute for Cancer Research/Cornell Medical School, where he was an Assistant Professor and then Associate Professor. Subsequently, Peter joined the biotechnology industry and was the Project Leader responsible for cloning the gene for M-CSF (Macrophage-Colony Stimulating Factor, a secreted cytokine which causes hematopoietic stem cells to differentiate into macrophages or other related cell types) at Cetus Corporation (which was later acquired by Novartis). Peter Ralph was subsequently employed at Genentech for nine years as Head, Research Immunology Department and in Genentech’s Bioassay Method Development.
Dr. Ralph has over 120 peer-reviewed publications and 24 issued patents. He is very well known for his development and patented methods to detect Herceptin and was the developer of the biometric GLP potency assay for Rituximab (anti-CD-20 human monoclonal antibody). During his 14-year tenure at Marin Biologic Laboratories he has expertly managed and successfully completed many hundreds of different projects for diverse clients, many of which were highly complex and intricate.
Dr. Mallavia performed his Ph.D. studies at the Autonoma University in Madrid (Spain) studying the effects of different inflammatory pathways over macrophage and muscle cells in the field of cardiovascular disease after obtaining his M.S. in Biology in the Complutense University also in Madrid. Following his research career, he moved to the Department of Medicine at the University of California San Francisco, where he continued his post-doctoral work studying different aspects of the innate and adaptive immune systems in the context of lung disease, especially after lung transplantation.
During his academic career Dr. Mallavia has published more than 25 peer reviewed papers and has developed different in vitro and in vivo assays from neutrophil extracellular DNA trap quantifications to different flavors of intra-vital life 2-photon microscopy methods.
In 2019, he joined Marin Biologic Laboratories to continue with the generation and development of different protocols and assays useful to many other companies.
But the most distinctive value of Dr. Mallavia is that he always wants to know WHY? Always willing to go the extra mile to answer the questions of HOW things work and WHERE can we improve things to make the experiment better, easier and simpler to understand.
Tonny Johnson completed his B.Sc. and M.Sc. from the University of Kerala, India and his Ph. D in Molecular Biology & Protein Biochemistry at the Bose Institute, University of Calcutta, India. Tonny did his post-doctoral work at Department of Biochemistry, University of Minnesota (St. Paul) and Department of Biochemistry & Molecular Genetics, University of Alabama at Birmingham. Tonny worked at Promega Corporation for eleven years as a Senior R&D Scientist, where he launched multiple research products for protein purification, cell-free protein expression, proteomics, and drug discovery assays. Tonny’s expertise spans protein biochemistry, proteomics, protein and antibody engineering, development of cell-free protein expression systems, monoclonal antibodies, ELISA development, in vitro and cell-based assay development, in vitro diagnostics (IVD), liquid biopsy, and epigenetics. He holds several issued patents and has authored numerous scientific papers and presentations.
Dr. Fraser earned his B.Sc.Hon, and Ph.D. from the University of British Columbia (Vancouver, Canada). After a research fellowship in transplantation immunology at Harvard Medical School, he held positions in both academic institutions (UIC, Chicago, IL / MIT, Cambridge, MA), and biotechnology companies including Millennium Pharmaceuticals, Combinatorx, and Selecta Biosciences. His career focused on research and drug development of small molecules and antibodies to treat immunological related indications such as auto-immune/inflammatory conditions, cancer, and vaccines. Dr. Fraser has extensive experience using in vitro primary immune cell and in vivo syngeneic and xenograft models for evaluating therapeutic drugs. His drug discovery efforts have covered a wide range of modalities such as small molecules targeting extracellular proteins and intracellular signaling molecules, bi- and tri-specific antibodies, immuno-cytokines, secreted proteins, gene therapy, stem cell therapy, and nanoparticles. Dr. Fraser has published 48 research articles in international peer-reviewed journals and has over 40 issued patents.
Warren Dang, B.Sc., M.Sc., MT(ASCP) Head of Quality
Warren Dang is a senior quality and compliance executive with over 25 years of experience supporting biotechnology, biopharmaceutical, and medical device organizations across the San Francisco Bay Area. He brings deep expertise in building and scaling inspection‑ready quality systems for regulated, growth‑stage companies.
Mr. Dang specializes in global QMS modernization, data integrity, and electronic QMS implementations, including Veeva, Qualio, and MasterControl. He has over a decade of hands‑on experience leading LIMS and CSV validation, analytical method validation, and pilot‑to‑commercial scale quality operations. His work has consistently enabled FDA inspection readiness through risk‑based compliance and “Right‑the-First‑Time” execution.
He is one of the inventors of three gene therapy plasmid DNA–liposome purification patents and the author of seven peer‑reviewed scientific publications involving cytokine and lymphokine research work. As Head of Quality at Marin Biologic Laboratories, Mr. Dang reports directly to the CEO and oversees QA/QC operations, CRO oversight, and regulatory documentation—ensuring operational readiness, regulatory compliance, and scale‑up execution.
Education/Certification
Michigan State University, Master of Science (MS), Biochemistry, Clinical Sciences
Michigan State University, Bachelor of Science (BS), Chemical Engineering
Accredited Lean Six Sigma Green Belt
MT(ASCP), certified medical technologist, California and Hawaii
